Literature DB >> 7850546

Cytokine-mediated gene therapy for cancer.

A R Miller1, W H McBride, K Hunt, J S Economou.   

Abstract

BACKGROUND: Significant interest has been generated in the gene therapy of cancer. One strategy involves tumor-directed cytokine gene transfer and its effects on tumor immunobiology.
METHODS: The authors review the current literature pertaining to cytokine gene therapy of cancer and provide a description of gene transfer methods currently being evaluated.
RESULTS: Several cytokine gene transfer models have been described involving at least 12 different cytokines. The introduction of cytokine genes into experimental animal tumors improves their ability to be recognized and destroyed by the host immune system. Certain cytokines will regulate phenotypic properties such as major histocompatibility complex antigens, immunosuppressive peptides, protooncogenes or endogenous cytokine production. Cytokine-transduced tumors attract an inflammatory exudate in vivo that generally results in tumor destruction. The nature of the infiltrate (lymphocytic, mononuclear, granulocytic) cannot always be predicted from the known biological properties of each cytokine. Untransduced bystander tumor cells are usually also destroyed. Some, but not all, cytokine transductions result in the generation of systemic major histocompatibility complex-restricted, tumor immunity. It has been hypothesized that the local continuous production of cytokines by tumor cells provides an optimal microenvironment for antigen recognition and the generation of T-cell immunity.
CONCLUSIONS: These experimental observations hold promise for the clinical application of genetically engineered tumor vaccines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7850546     DOI: 10.1007/bf02303818

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  134 in total

1.  IL-4 down-regulates IL-1 and TNF gene expression in human monocytes.

Authors:  R Essner; K Rhoades; W H McBride; D L Morton; J S Economou
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

2.  Interleukin 4 mediates autocrine growth of helper T cells after antigenic stimulation.

Authors:  R Fernandez-Botran; V M Sanders; K G Oliver; Y W Chen; P H Krammer; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

Review 3.  Role of the major histocompatibility complex class I antigens in tumor growth and metastasis.

Authors:  K Tanaka; T Yoshioka; C Bieberich; G Jay
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

Review 4.  The panspecific hemopoietin of activated T lymphocytes (interleukin-3).

Authors:  J W Schrader
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

5.  Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells.

Authors:  E C Borden; T F Hogan; J G Voelkel
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

6.  Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function.

Authors:  S Iho; H Y Shau; S H Golub
Journal:  Cell Immunol       Date:  1991-06       Impact factor: 4.868

Review 7.  Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.

Authors:  S Wadler; E L Schwartz
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

8.  Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer.

Authors:  A Douvdevani; M Huleihel; M Zöller; S Segal; R N Apte
Journal:  Int J Cancer       Date:  1992-07-09       Impact factor: 7.396

9.  A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.

Authors:  N P Restifo; P J Spiess; S E Karp; J J Mulé; S A Rosenberg
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

10.  Antitumor activity of recombinant interleukin 6 in mice.

Authors:  J J Mulé; J K McIntosh; D M Jablons; S A Rosenberg
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Recent advances in the treatment of malignant melanoma with gene therapy.

Authors:  E M Hersh; A T Stopeck
Journal:  Mol Med       Date:  1997-10       Impact factor: 6.354

Review 2.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells.

Authors:  A Aruga; S Shu; A E Chang
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

4.  Alteration of tumour response to radiation by interleukin-2 gene transfer.

Authors:  J Lee; J P Moran; B M Fenton; C J Koch; J G Frelinger; P C Keng; E M Lord
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

5.  CDCA4 as a novel molecular biomarker of poor prognosis in patients with lung adenocarcinoma.

Authors:  Jianlong Tan; Fengyu Chen; Bin Ouyang; Xiuying Li; Weidong Zhang; Xinglin Gao
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.